Hepatitis C Infection Associated with Renal Disease and Chronic Renal Failure

Screening of blood products and attention to stricter infection control measures in hemodialysis units have reduced the incidence of hepatitis C virus (HCV) infection among dialysis patients. HCV can be transmitted via transplanted organs. Renal transplantation may accelerate the course of liver disease, which has an impact on patient and graft survival. Interferon (IFN) alfa monotherapy has produced promising results during treatment but disappointing long-term results in patients with HCV-associated glomerulonephritis. Dialysis patients with HCV infection respond well to IFN-based therapy, and there appears to be clinical benefit in clearing HCV in renal transplantation candidates. Larger prospective trials are required to fully determine the role of IFN in these patient groups, including the potential use of IFN plus ribavirin and pegylated IFNs. IFN therapy in renal transplantation patients is not recommended because of potential graft rejection.

HCV - chronic renal failure - renal disease - renal transplantation - interferon

REFERENCES

• 1 Fabrizi F, Martin P, Lunghi G, Ponticelli C. Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: clinical perspectives.  Int J Artif Organs. 2000;  23 805-816
• 2 Fabrizi F, Martin P, Dixit V et al.. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay.  Am J Kidney Dis. 1998;  31 647-654
• 3 Lombardi M, Cerrai T, Geatti S et al.. Results of a national epidemiological investigation on HCV infection among dialysis patients.  J Nephrol. 1999;  12 322-327
• 4 Maisonneuve P, Agodoa L, Gellert R et al.. Cancer in patients on dialysis for end-stage renal disease. An international collaborative study.  Lancet. 1999;  354 93-99
• 5 Espinosa M, Martin-Malo A, Alvarez de Lara M, Alijama P. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients.  Nephrol Dial Transplant. 2001;  16 1669-1674
• 6 Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy.  J Am Soc Nephrol. 2000;  11 1896-1902
• 7 Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation.  Am J Kidney Dis. 2001;  38 919-934
• 8 Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. The Universitaries Cliniques St-Luc (UCL) Collaborative Group.  Kidney Int. 1998;  53 1022-1025
• 9 Schneeberger P M, Keur I, van Loon A M et al.. The prevalence and incidence of hepatitis C virus infection among dialysis patients in the Netherlands: a nationwide prospective study.  J Infect Dis. 2000;  182 1291-1299
• 10 Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study.  J Med Virol. 2000;  61 44-51
• 11 Qian K P, Natov S N, Pereira B J, Lau J Y. Hepatitis C virus mixed genotype infection in patients on haemodialysis.  J Viral Hepat. 2000;  7 153-160
• 12 Todorov V, Boneva R, Ilieva P et al.. High prevalence of hepatitis C virus infection in one dialysis center in Bulgaria.  Nephron. 1998;  79 222-223
• 13 Djordjevic V, Stojanovic K, Stojanovic M, Stefanovic V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study.  Int J Artif Organs. 2000;  23 181-188
• 14 Covic A, Iancu L, Apetrei C et al.. Hepatitis virus infection in haemodialysis patients from Moldavia.  Nephrol Dial Transplant. 1999;  14 40-45
• 15 Valtuille R, Moretto H, Lef L et al.. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow up.  Clin Nephrol. 2002;  57 371-375
• 16 Marcelli D, Stanhard D, Conte F et al.. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.  Kidney Int. 1996;  50 1013-1018
• 17 Stehman-Breen C O, Emerson S, Gretch D, Johnson R J. Risk of death among chronic dialysis patients infected with hepatitis C virus.  Am J Kidney Dis. 1998;  32 629-634
• 18 Fabrizi F, Lunghi G, Guarnori I et al.. Virological characteristics of hepatitis C virus infection in chronic hemodialysis patients: a cross-sectional survey.  Clin Nephrol. 1995;  44 49-55
• 19 Picciotto A, Varagona G, Gurreri G et al.. Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in hemodialysis patients.  Nephrol Dial Transplant. 1993;  8 1115-1117
• 20 Pol S, Romeo R, Zins B et al.. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications.  Kidney Int. 1993;  44 1097-1100
• 21 Chan T M, Lok A SF, Cheng I KP, Chan R T. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays.  Hepatology. 1993;  17 5-8
• 22 Bukh J, Wantzin P, Krogsgaard K et al.. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number with HCV infection.  J Infect Dis. 1993;  168 1343-1348
• 23 Fabrizi F, Martin P, Dixit V et al.. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey.  Nephron. 1998;  80 428-433
• 24 Martin P, Carter D, Fabrizi F et al.. Histopathological features of hepatitis C in renal transplant candidates.  Transplantation. 2000;  69 1479-1484
• 25 Sterling R K, Sanyal A J, Luketic V A et al.. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation.  Am J Gastroenterol. 1999;  94 3576-3582
• 26 Saab S, Martin P, Brezina M et al.. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis.  Am J Kidney Dis. 2001;  37 308-315
• 27 Saab S, Brezina M, Gitnick G et al.. Hepatitis C screening strategies in hemodialysis patients.  Am J Kidney Dis. 2001;  38 91-97
• 28 Fabrizi F, Martin P, Dixit V et al.. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus.  Am J Kidney Dis. 2000;  35 122-129
• 29 Fabrizi F, Martin P, Dixit V et al.. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients.  Am J Nephrol. 1999;  19 383-388
• 30 Koenig P, Vogel W, Umlauft F et al.. Interferon treatment for chronic hepatitis C virus infection in uremic patients.  Kidney Int. 1994;  45 1507-1509
• 31 Pol S, Thiers V, Carnot F et al.. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients.  Kidney Int. 1995;  47 1412-1418
• 32 Raptopoulou-Gigi M, Spaia S, Garifallos A et al.. Interferon-alpha2b treatment of chronic hepatitis C in haemodialysis patients.  Nephrol Dial Transplant. 1995;  10 1834-1837
• 33 Fernandez J L, Rendo P, Del Pino N. Nephrologists' group for the study of HCV infection . Viola L. A double-blind controlled trial of recombinant interferon-alpha2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels.  J Viral Hep. 1997;  4 113-119
• 34 Izopet J, Rostaing L, Moussion F et al.. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-therapy.  J Infect Dis. 1997;  176 1614-1617
• 35 Chan T M, Wu P C, Lau J YN, Lok A SF, Lai C L, Cheng K P. Interferon treatment for hepatitis C virus infection in patients on haemodialysis.  Nephrol Dial Transplant. 1997;  12 1414-1419
• 36 Uchihara M, Izumi N, Sakai Y et al.. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon.  Nephron. 1998;  80 51-56
• 37 Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti P B. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C.  Curr Med Res Opin. 1998;  14 141-144
• 38 Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C.  Am J Nephrol. 2001;  21 435-440
• 39 Campistol J M, Esforzado N, Martinez J et al.. Efficacy and tolerance of interferon-a2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.  Nephrol Dial Transplant. 1999;  14 2704-2709
• 40 Espinosa M, Rodriguez M, Martin-Malo A et al.. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.  Clin Nephrol. 2001;  55 220-226
• 41 Casanovas-Taltavull T, Baliellas C, Benasco C et al.. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidneys transplant candidates on hemodialysis: results after transplantation.  Am J Gastroenterol. 2001;  96 1170-1177
• 42 Hanrotel C, Toupance O, Lavaud S et al.. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.  Nephron. 2001;  88 120-126
• 43 Degos F, Pol S, Chaix M L et al.. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study.  Nephrol Dial Transplant. 2001;  16 1017-1023
• 44 Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.  Aliment Pharmacol Ther. 2003;  18 1071-1081
• 45 Russo M W, Goldsweig C D, Jacobson I M, Brown R S. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.  Am J Gastroenterol. 2003;  98 1610-1615
• 46 Izzedine H, Lebon P, Launay-Vacher V et al.. Tolerance and pharmacokinetics of high doses of interpheron-alpha-2a in a hemodialysis patient.  Nephron. 2001;  87 91-92
• 47 Hirsch M S, Tolkoff-Rubin N E, Kelly A P, Rubin R H. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis.  J Infect Dis. 1983;  148 335
• 48 Rostaing L, Chatelut E, Payen J L et al.. Pharmacokinetics of alfa IFN-2b in chronic hepatitis C virus undergoing chronic hemodialysis or with normal renal function: clinical implications.  J Am Soc Nephrol. 1998;  9 2344-2348
• 49 Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.  Nephrol Dial Transplant. 2001;  16 1729
• 50 Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study.  J Viral Hepat. 2001;  8 287-292
• 51 Tan A C, Brouwer J T, Glue P et al.. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.  Nephrol Dial Transplant. 2001;  16 193-195
• 52 Reddy K R. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs.  Ann Pharmacother. 2000;  34 915-923
• 53 Martin P, Mitra S, Farrington K et al.. Pegylated (40KDA) interferon alfa-2a (Pegasys) is unaffected by renal impairment.  Hepatology. 2000;  32 370A
• 54 Lamb M W, Marks I M, Wynohradnyk L et al.. 40 kDa peginterferon alfa-2a (Pegasys) can be administered safely in patients with end-stage renal disease.  Hepatology. 2001;  34 326A
• 55 Bunnapradist S, Fabrizi F, Vierling J et al.. Hepatitis C therapy with long term remission after renal transplantation.  Int J Artif Organs. 2002;  25 1189-1193
• 56 Pereira B J, Levey A S. Hepatitis C virus infection in dialysis and renal transplantation.  Kidney Int. 1997;  51 981-999
• 57 Zucker K, Cirocco R, Roth D et al.. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation.  Transplantation. 1994;  57 832-840
• 58 Roth D, Fernandez J A, Babishkin S et al.. Transmission of hepatitis C virus solid organ transplantation: incidence and clinical significance.  Transplant Proc. 1993;  25 1476-1477
• 59 Tesi R J, Waller K, Morgan M L, Ferguson R M. Transmission of hepatitis C by kidney transplantation-the risks.  Transplantation. 1994;  57 826-831
• 60 Vincenti F, Lake J, Wright T et al.. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients.  Transplantation. 1993;  55 674-675
• 61 Fabrizi F, Marai P, Raffaele L et al.. Hepatitis C virus infection in kidney graft recipients: a study with second-generation assays.  Nephrol Dial Transplant. 1992;  7 1164-1165
• 62 Rostaing L, Izopet J, Cisterne J M et al.. Prevalence of antibodies to hepatitis C virus and correlation with liver disease in renal transplant patients.  Am J Nephrol. 1997;  17 46-52
• 63 Lau J YN, Davis G L, Brunson M E et al.. Hepatitis C virus infection in kidney transplant recipients.  Hepatology. 1993;  18 1027-1031
• 64 Roth D, Zucker K, Cirocco R et al.. The impact of hepatitis C virus infection on renal allograft recipients.  Kidney Int. 1994;  45 238-244
• 65 Chan T M, Lok A SF, Chang I KP. Hepatitis C in renal transplant recipients.  Transplantation. 1991;  52 810-813
• 66 Mahmoud I, Sobh M A, Am G M et al.. Prospective study of hepatitis C viremia in renal allograft recipients.  Am J Nephrol. 1999;  19 576-585
• 67 Pereira B J, Natov S N, Bouthot B A et al.. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group.  Kidney Int. 1998;  53 1374-1381
• 68 Knoll G A, Tankersley M R, Lee J Y et al.. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients.  Am J Kidney Dis. 1997;  29 608-614
• 69 Kliem V, van den Hoff U, Brunkhorst R et al.. The long-term course of hepatitis C after kidney transplantation.  Transplantation. 1996;  62 1417-1421
• 70 Gentil M A, Rocha J L, Rodriguez-Algarra G et al.. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus.  Nephrol Dial Transplant. 1999;  14 2455-2460
• 71 Mathurin P, Mouquet C, Poynard T et al.. Impact of hepatitis B and C virus on kidney transplantation outcome.  Hepatology. 1999;  29 257-263
• 72 Batty D S, Swanson S J, Kirk A D et al.. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival.  Am J Transplant. 2001;  1 179-184
• 73 Rostaing L, Izopet J, Baron E et al.. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.  Transplantation. 1995;  59 1426-1431
• 74 Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C.  Nephrol Dial Transplant. 1995;  10 2104-2106
• 75 Thervet E, Pol S, Legendre C et al.. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study.  Transplantation. 1994;  58 625-628
• 76 Garnier J L, Chevallier P, Dubernard J M et al.. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients.  Transplant Proc. 1997;  29 783
• 77 Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights.  Nephrol Dial Transplant. 2000;  15 74-76
• 78 Misiani R, Bellavita P, Fenili D et al.. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.  N Engl J Med. 1994;  330 751-756
• 79 Ferri C, Marzo E, Longombardo G. Interpheron alpha in mixed cryoglobulinemia patients: a randomized, cross-over controlled trial.  Blood. 1993;  81 1132-1136
• 80 Dammacco F, Sansonno D, Han J H et al.. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type-II mixed cryoglobulinemia: a long-term, randomized, controlled study.  Blood. 1994;  84 3336-3343
• 81 Johnson R J, Gretch D R, Couser W G et al.. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy.  Kidney Int. 1994;  46 1700-1704
• 82 Misiani R, Bellavita P, Baio P et al.. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin.  Nephrol Dial Transplant. 1999;  14 1558-1560
• 83 Quigg R J, Brathwaite M, Gardner D F et al.. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection.  Am J Kidney Dis. 1995;  25 798-800
• 84 Gilli P, Stabellini N, Storari A et al.. Effect of human leukocyte alpha interferon on cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection.  Nephrol Dial Transplant. 1996;  11 526-538
• 85 Sarac E, Bastacky S, Johnson J P. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection.  Am J Kidney Dis. 1997;  30 113-115
• 86 Yamabe H, Johnson R J, Gretch D R et al.. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha.  Am J Kidney Dis. 1995;  25 67-69
• 87 Morosetti M, Sciarra G, Meloni C et al.. Membranoproliferative glomerulonephritis and hepatitis C: Effects of interferon-alpha therapy on clinical outcome and histologic pattern.  Nephrol Dial Transplant. 1996;  11 532-534
• 88 Garini G, Allegri L, Carnevali L et al.. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C-virus associated cryoglobulinemic membranoproliferative glomerulonephritis.  Am J Kidney Dis. 2001;  38 E35
• 89 D’Amico G. Nephrology forum: renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis.  Kidney Int. 1998;  54 650-671
• 90 Baid S, Cosimi A B, Tolkoff-Rubin N et al.. Renal disease associated with hepatitis C infection after kidney and liver transplantation.  Transplantation. 2000;  70 255-261
• 91 Davis C L, Gretch D R, Perkins J D et al.. Hepatitis C-associated glomerular disease in liver transplant recipients.  Liver Transpl Surg. 1995;  3 166-175
• 92 Kendrick E A, McVicar J P, Kowdley K V et al.. Renal disease in hepatitis C-positive liver transplant recipients.  Transplantation. 1997;  63 1287-1293
• 93 Pham H P, Feray C, Samuel D et al.. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.  Kidney Int. 1998;  54 1311-1319